48 completed, 9 terminated, 5 recruiting, 4 active not recruiting. 35 Phase 1, 26 Phase 2, 5 Phase 3, 2 Phase 4, 1 Not applicable.
Follow bosutinib: new trials by email Literature Review of bosutinib trials Research Report on bosutinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy TKIs - Chronic Myelogenous Leukemia - Chronic Phase | Recruiting | Novartis Pharmaceuticals | 1000 | 2025-12-17 | 2026-07-20 | |
| A Study to Learn About the Study Medicine Bosulif in Adult Patients With Chronic Myeloid Leukemia(CML). Bosulif - Chronic Leukemia Myelogenous | Recruiting | Pfizer | 600 | 2025-01-20 | 2026-04-14 | |
| Study of Olverembatinib (HQP1351) in Patients With CML-CP olverembatinib, Bosutinib - Chronic Myeloid Leukemia, CML | Phase 3 | Recruiting | Ascentage Pharma Group Inc. | 333 | 2024-02-05 | 2026-09-15 |
| Asciminib Roll-over Study Asciminib single agent, Imatinib, Nilotinib - Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive | Phase 4 | Recruiting | Novartis Pharmaceuticals | 347 | 2022-08-30 | 2026-07-06 |
| Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation Bosutinib Monohydrate, Decitabine, Enasidenib Mesylate - Recurrent Acute Myeloid Leukemia | Phase 1 | Withdrawn | City of Hope Medical Center | 2022-06-25 | 2022-06-09 | |
| Evaluation of the Relative Bioavailability of Bosutinib Capsules Under Fed Condition and Estimation of Food Effect on Orally Administered Bosutinib Capsule Bosutinib capsule, Bosutinib - Healthy Participants | Phase 1 | Completed | Pfizer | 32 | 2022-01-19 | 2024-09-20 |
| A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP Imatinib, Nilotinib, Bosutinib - Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 405 | 2021-10-06 | 2026-08-28 |
| Bioavailability of Bosutinib Administered as Capsule Contents Mixed With Applesauce or Yogurt Relative to Intact Capsules Under Fed Condition Bosutinib capsule - Healthy Participants | Phase 1 | Completed | Pfizer | 18 | 2021-08-13 | 2024-11-07 |
| Safety and Efficacy Evaluation of Bosutinib Plus Atezolizumab in Newly Diagnosed Chronic Leukemia Adult Patients Bosutinib 400 MG Monotherapy, Bosutinib 400 MG + Atezolizumab 840 MG in 14 ML Injection - Chronic Phase-Chronic Myeloid Leukemia | Phase 1 / Phase 2 | Terminated | Fundacion Espanola para la Curacion de la Leucemia Mieloide Cronica | 9 | 2021-02-24 | 2024-03-19 |
| Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Withdrawal, Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Re-initiation - Chronic Myeloid Leukemia, Chronic Myeloid Leukemia, BCR/ABL-Positive, in Remission | Phase 2 | Active not recruiting | Baylor College of Medicine | 17 | 2020-12-22 | 2026-05-04 |
| Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database Bosutinib, Imatinib, Nilotinib - Chronic Myeloid Leukaemia | Completed | Pfizer | 1484 | 2020-11-18 | 2023-10-27 | |
| Bioequivalence Study of Bosutinib Pediatric Capsule Relative to Commercial Tablet Under Fed Condition Bosutinib capsule, Bosutinib tablet - Healthy Participants | Phase 1 | Completed | Pfizer | 66 | 2020-09-16 | 2022-02-16 |
| Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Eicosapentaenoic Acid, Tyrosine kinase inhibitor - Chronic Myeloid Leukemia, Chronic Phase | Phase 1 / Phase 2 | Terminated | Milton S. Hershey Medical Center | 1 | 2020-09-14 | 2022-07-01 |
| Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia Bosutinib - Philadelphia Chromosome Positive CML, Accelerated Phase Chronic Myelogenous Leukemia | Phase 1 / Phase 2 | Active not recruiting | Children's Oncology Group | 60 | 2020-07-06 | 2026-10-01 |
| A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib) Imatinib, Nilotinib, Dasatinib - Chronic Myeloid Leukemia, Chronic Myeloid Leukemia in Remission | Phase 2 | Unknown | National Research Center for Hematology, Russia | 100 | 2020-01-15 | 2020-10-08 |
| Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors Bosutinib, Pemetrexed - Carcinoma, Non-Small-Cell Lung, Mesothelioma | Phase 1 | Completed | Nagla Abdel Karim | 6 | 2019-12-10 | 2022-06-14 |
| Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients Bosutinib, Dasatinib, Imatinib - CML, Chronic Phase, CML (Chronic Myelogenous Leukemia | Completed | UNC Lineberger Comprehensive Cancer Center | 45 | 2019-06-20 | 2023-01-11 | |
| Retrospective Observational Research Study to Describe the Real World Use of Bosutinib in a Single Centre in Scotland Bosutinib - Myeloid Leukemia | Completed | Pfizer | 17 | 2019-05-01 | 2026-06-29 | |
| Impact of Bosutinib on Safety, Tolerability, Biomarkers and Clinical Outcomes in Dementia With Lewy Bodies Placebo Oral Tablet, Bosutinib Oral Tablet - Dementia With Lewy Bodies | Phase 2 | Completed | Georgetown University | 26 | 2019-04-23 | 2026-07-10 |
| WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor Palbociclib, Bosutinib, Fulvestrant - Metastatic Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Phase 1 | Completed | Georgetown University | 19 | 2019-04-01 | 2025-02-06 |
Showing 20 of 70. Sign in to see all of them.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive (27) · Leukemia, Myeloid, Chronic-Phase (9) · Breast Neoplasms (6) · Leukemia (5) · Blast Crisis (4) · Philadelphia Chromosome (4) · Bronchiolitis Obliterans Syndrome (3) · Neoplasms (3) · Leukemia, Myeloid (2) · Leukemia, Myeloid, Accelerated Phase (2) · Neoplasm Metastasis (2) · Acute Kidney Injury (1) · Amyotrophic Lateral Sclerosis (1) · Bone Marrow Diseases (1) · Carcinoma, Non-Small-Cell Lung (1)
Pfizer (27) · Wyeth is now a wholly owned subsidiary of Pfizer (13) · Novartis Pharmaceuticals (4) · M.D. Anderson Cancer Center (3) · Georgetown University (2) · Ascentage Pharma Group Inc. (1) · Baylor College of Medicine (1) · Canadian Cancer Trials Group (1) · Children's Oncology Group (1) · City of Hope Medical Center (1) · Fundacion Espanola para la Curacion de la Leucemia Mieloide Cronica (1) · Gruppo Italiano Malattie EMatologiche dell'Adulto (1) · Kyoto University (1) · Massachusetts General Hospital (1) · Medical College of Wisconsin (1)
United States (44) · Spain (15) · Italy (13) · United Kingdom (13) · Belgium (11) · Canada (11) · France (11) · Australia (10) · Germany (10) · Hungary (10) · Poland (10) · Japan (9) · Netherlands (9) · Singapore (9) · South Korea (9)
Andrew H. Ko, MD (1) · Anna Turkina, Professor (1) · Carlo Gambacorti-Passerini, MD (1) · Claudine Isaacs, MD (1) · Daniel Crona, PharmD, PhD (1) · Daniel J Renouf (1) · Dominik GF Wolf, Prof. Dr. (1) · Ehab Atallah, MD (1) · Elias Jabbour, M.D. (1) · Fausto Castagnetti (1) · Fernando L Pagan, MD (1)
PMID 35235189, PMID 24919837, PMID 37553873, PMID 23116602, PMID 21865346, PMID 22036634, PMID 22371878, PMID 22825216, PMID 22884766, PMID 22949154, PMID 23839484, PMID 24345751, PMID 24674873, PMID 24674874, PMID 24711212, PMID 24944159, PMID 25290090, PMID 25540064, PMID 25635231, PMID 25803093, PMID 27045164, PMID 27531525, PMID 27717999, PMID 27718000, PMID 28409328, PMID 28838955, PMID 29058816, PMID 29072772, PMID 29091516, PMID 29609532, PMID 29773593, PMID 32279228, PMID 32572189, PMID 33180106, PMID 33513367, PMID 33851349, PMID 34407542, PMID 34673442, PMID 35643868, PMID 35764773, PMID 35963986, PMID 36168187, PMID 36467452, PMID 36524980, PMID 37431294, PMID 38007586, PMID 38033284, PMID 38484432, PMID 38820078, PMID 39164407
2023 (3), 2014 (2), 2016 (2), 2018 (2), 2005 (1), 2008 (1), 2015 (1), P30CA016672 (1), P30CA033572 (1), U10CA180888 (1)